Palopegteriparatide is a TransCon prodrug of PTH(1-34), sold as Yorvipath. FDA approved it in August 2024 for hypoparathyroidism in adults (FDA, 2024). It is not teriparatide for osteoporosis, and it is not a research-catalog PTH fragment.

TL;DR

  • Hypoparathyroidism is a PTH deficit. Low PTH drops serum calcium and raises phosphate. Standard care has been active vitamin D plus large, split calcium doses (FDA, 2024).
  • Palopegteriparatide transiently conjugates PTH(1-34) to a branched 40 kDa mPEG carrier. Average molecular weight is about 47.4 kDa. At physiologic pH the linker autocleaves and releases PTH(1-34) (FDA label).
  • Released PTH has an apparent half-life of about 60 hours, with median Tmax of 4 hours (range 4 to 8) and steady state after 7 days. That is a continuous 24-hour exposure, not a Forteo pulse (FDA label).
  • Study 1 / PaTHway (n=82): the labeled composite at week 26 was 68.9% (42/61) on drug versus 4.8% (1/21) on placebo, difference 64.2% (95% CI 49.5% to 78.8%) (FDA label; Khan et al., 2023).
  • A research vial marked “PTH(1-34)” or “teriparatide” is not Yorvipath. It is also not a gym peptide.

Educational only. Not medical advice, not a protocol, and not a reason to inject a catalog analog.

How is palopegteriparatide different from teriparatide (Forteo)?

Teriparatide is unmodified PTH(1-34). Palopegteriparatide is that same 34-residue sequence parked behind a proprietary TransCon linker and an inert branched 40 kDa methoxypolyethylene glycol (mPEG) carrier, two 20 kDa arms (FDA label).

The intact prodrug is essentially inactive. The PEG shield keeps PTH(1-34) off parathyroid hormone 1 receptor (PTH1R) until the linker autocleaves at physiologic conditions and dumps free peptide (Karpf et al., 2020; FDA label).

Released PTH(1-34) then hits PTH1R on osteoblasts, osteocytes, and renal tubular cells. The label’s downstream effects are the familiar PTH set: more bone turnover, more renal calcium reabsorption, more phosphate excretion, and more 1,25-dihydroxyvitamin D synthesis (FDA label).

Forteo is an osteoporosis anabolic given as a short pulse. Yorvipath is a replacement prodrug built for continuous exposure in adults who lack PTH, same 34 residues, different clock and indication.

For the amino-acid primer, see Peptides 101. For other half-life tricks, see the DAC, PEGylation, and lipidation guide.

Why does native PTH fail as a once-daily shot?

Unmodified PTH(1-34) is short. Karpf’s first-in-human paper framed TransCon PTH as a sustained-release, essentially inactive prodrug meant to hold PTH in a physiologic band for 24 hours, closer to a continuous subcutaneous infusion than to a bolus (Karpf et al., 2020).

The chemistry is transient PEGylation, not a fatty-acid albumin ride. Formulation pH on the label is 3.7 to 4.3, which keeps the conjugate more stable in the cartridge until physiologic pH and temperature trigger cleavage (FDA label).

After subcutaneous dosing, PTH Cmax and AUC rose in proportion from 12 to 24 mcg/day, with an apparent half-life of about 60 hours (FDA label). That long clock is why a once-daily pen can cover the day, and why calcium moves in both directions if the dose or the conventional supplements change too fast.

What did PaTHway actually measure?

Study 1 (NCT04701203) was a 26-week, randomized, double-blind, placebo-controlled trial in 82 adults with hypoparathyroidism. Sixty-one received palopegteriparatide and 21 received placebo, both starting at 18 mcg/day plus conventional calcium and active vitamin D, then titrated (FDA label).

Mean age was 49 years (range 19 to 78). Seventy-eight percent were female, 93% Caucasian, 85% postsurgical, median duration 8.5 years (FDA label).

The labeled primary endpoint was a week-26 composite, not a symptom score. Responders had to keep albumin-corrected calcium in 8.3 to 10.6 mg/dL, drop active vitamin D, keep elemental calcium at or below 600 mg/day, avoid a study-drug increase after week 22, and stay at or below 30 mcg/day.

Source Design Primary finding
Karpf 2020, phase 1 Healthy adults, TransCon PTH Inactive PEG prodrug. Designed for stable 24-hour PTH(1-34) exposure.
Khan 2023, PaTHway 26 weeks, n=82, 3:1 Phase 3 publication of the same program FDA later labeled.
FDA label, Study 1 composite Week 26, 61 vs 21 68.9% (42/61) vs 4.8% (1/21). Difference 64.2% (95% CI 49.5% to 78.8%).
FDA label, components Same trial Normal calcium 80.3% vs 47.6%. Off active vitamin D 95.1% vs 23.8%. Therapeutic calcium independence 86.9% vs 4.8%.
FDA label, extension Open-label, same cohort With later up-titration allowed, 64% at week 52 and 66% at week 78 kept normocalcemia plus independence from active vitamin D and therapeutic calcium.

FDA’s public summary used the same 69% versus 5% contrast: maintain calcium in range without active vitamin D and without high-dose calcium (FDA, 2024). The product was not studied in acute post-surgical hypoparathyroidism (FDA label).

What does continuous PTH1R signaling cost?

PTH biology moves calcium. The label has no boxed warning, but it warns on serious hypercalcemia and hypocalcemia, rat osteosarcoma findings with PTH analogs, orthostatic hypotension, and digoxin toxicity if calcium rises (FDA label).

Injection-site reactions were 39% versus 5% on placebo. Vasodilatory signs were 28% versus 0, and headache was 21% versus 10% (FDA label).

Albumin-corrected calcium above 10.6 mg/dL showed up in 54.1% versus 9.5%, and values above 12 mg/dL in 13.1% versus 0. Symptomatic hypercalcemia occurred in 8% on drug, all in the first three months (FDA label).

The osteosarcoma language is class PTH-analog language from rat studies, including teriparatide. This is adult hypoparathyroidism replacement, not a bone-anabolic protocol and not a pediatric growth peptide.

Is a catalog PTH(1-34) vial the same peptide?

No. Yorvipath is a defined PEG-linker prodrug in a 14-dose prefilled pen, with labeled strengths, a hypoparathyroidism indication, and a titration scheme tied to albumin-corrected calcium. A lyophilized “PTH(1-34)” or “teriparatide” research vial is a different molecule the moment the carrier is missing, and it is not an FDA-approved drug.

How a lab builds a research peptide is a different conversation from how a licensed conjugate is filled. See how peptides are made, the reconstitution guide, and the calculator for dissolving a lyophilized vial. Licensed product still comes through a prescriber and the provider directory, not a research catalog.

Bottom line

Palopegteriparatide is a PEG-shielded PTH(1-34) prodrug that releases peptide over a roughly 60-hour half-life so adults with hypoparathyroidism can keep calcium in range without active vitamin D. The labeled week-26 number is 68.9% versus 4.8% on a strict composite, and a catalog teriparatide vial is not that product.

Educational only. Not medical advice.